Data compiled by Redley Lamar · ChainSifter Intelligence
7Suppliers
7Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Neumora Therapeutics, Inc. (NMRA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
18Total relationships
2Distinct source URLs
9High confidence
0.768Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from AMGN graph: Reciprocal relationship from NMRA graph: Additionally, Amgen purchased 12.7 million shares of our Series A-2 Preferred Stock at a purchase price of $7.85 per …
Additionally, Amgen purchased 12.7 million shares of our Series A-2 Preferred Stock at a purchase price of $7.85 per share, for total consideration of $100.0 million.
VANDERBILT
VANDERBILT
90%
In November 2023 and July 2025, a $2.0 and $5.0 million, respectively, development milestone was paid to Vanderbilt under the Vanderbilt License Agreement.
BLACKTHORN-THERAPEUTICS-INC
BLACKTHORN-THERAPEUTICS-INC
85%
The Company acquired BlackThorn for its in-process research and development programs, including an antagonist of the kappa opioid receptor ('navacaprant' or 'NMRA-140') for the treatment of MDD and a…
TSRI
TSRI
80%
Pursuant to the 2015 TSRI License Agreement, TSRI granted us a worldwide, exclusive license under certain patent rights and a worldwide, non-exclusive license under certain know-how relating to TSRI'…
Reciprocal relationship from MPLT graph: . Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require u…
Reciprocal relationship from NBP graph: Reciprocal relationship from NMRA graph: Reciprocal relationship from NBP graph: Reciprocal relationship from NMRA graph: Reciprocal relationship from NBP grap…
Reciprocal relationship from XENE graph: Reciprocal relationship from NMRA graph: Reciprocal relationship from XENE graph: velopment and marketing efforts of our collaborators. • Our reliance on thir…
ASSETS-BLACKTHORN-THERAPEUTICS-INC
ASSETS-BLACKTHORN-THERAPEUTICS-INC
62%
linical costs 15,956 $ 11,606 Compensation and benefits 11,494 9,975 Other 724 $ 326 Professional services 614 2,686 Total accrued liabilities $ 28,788 $ 24,593 7. Acquisitions of Assets BlackThorn T…
BLACKTHORN-THERAPEUTICS-INC
BLACKTHORN-THERAPEUTICS-INC
62%
linical costs 15,956 $ 11,606 Compensation and benefits 11,494 9,975 Other 724 $ 326 Professional services 614 2,686 Total accrued liabilities $ 28,788 $ 24,593 7. Acquisitions of Assets BlackThorn T…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
is Quarterly Report on Form 10-Q: • the commencement of, enrollment in, or results of current and future preclinical studies and clinical trials we may conduct, or changes in the development status o…
K2-HEALTHVENTURES-LLC
K2-HEALTHVENTURES-LLC
62%
incentive for employees, directors, and service providers. The Company accounts for all stock-based awards based on their fair value on the date of the grant. For stock-based awards with service only…
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
62%
property and technology, which would harm our business. Risks Related to Our Limited Operating History, Financial Condition and Need for Additional Capital We are a clinical stage biopharmaceutical c…
RESEARCH-VENTURES-LIMITED
RESEARCH-VENTURES-LIMITED
62%
. In addition, the Company also has an exclusive option to negotiate an exclusive license to certain patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored res…
Neumora Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
NMRA-DEBT-11312
Warrants outstanding: 1613000
90%
xbrl warrant detail from xbrl 2022-12-31.
NMRA-DEBT
Debt stack $112.9M
90%
Market cache reports total debt of $112.9M.
NMRA-DEBT-20260
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
Neumora Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Neumora Therapeutics, Inc..
Neumora Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
NMRA-OWNER-PERCEPTIVE-ADVISORS-LLC
PERCEPTIVE ADVISORS LLC
90%
13F overlay lists PERCEPTIVE ADVISORS LLC as top holder; 117 tracked holders.
Neumora Therapeutics, Inc. Extended Supply Chain Network
